Bactolife^TM was established in 2017 by a group of senior executives from the biotech industry together with top scientific talents, with the aim of adding a new approach to improving gastrointestinal health for animals and humans in a manner that is safe, cost efficient, and does not create antimicrobial resistance (AMR). Bactolife^TM has developed a pipeline of projects within animal and human health based on its VIP^TM technology where specially designed proteins protect the microbiome by inactivation of pathogenic virulence factors leaving the healthy microbiome intact.